CJC-1295 WITH DAC 5 mg

CJC-1295 DAC 5 mg reagent - characteristics

CJC-1295 DAC 5 mg is a synthetic research peptide included in the group of long-acting growth hormone-releasing hormone analogues (GHRH / GRF). This molecule was developed as a modified analogue of the hGRF(1-29) with an additional component DAC (Drug Affinity Complex), which enables permanent binding to endogenous albumin and forms the basis for its classification as a peptide with prolonged biological activity. In experimental studies CJC-1295 DAC 5 mg is analysed primarily in the context of prolonged axis stimulation GH/IGF-1, regulation of growth hormone secretion and the relationship between peptide pharmacokinetics and endocrine response.

In the scientific literature, the peptide CJC-1295 DAC 5 mg is primarily described in terms of mechanisms related to activation of the GHRH receptor on pituitary somatotropic cells and a secondary increase in secretion of the GH i IGF-1. Key clinical studies indicated that subcutaneous administration of CJC-1295 led to long-lasting, dose-dependent increases in GH and IGF-1 concentrations in healthy adults, while maintaining the pulsatile nature of GH secretion despite continuous stimulation. It is the combination of long-lasting action with preservation of pulsatile secretion that is one of the most important elements of scientific interest in this molecule.

An important area of scientific interest also remains the relationship between activity CJC-1295 with DAC 5 mg and its pharmacokinetic properties due to the presence of DAC. Publications on the design of this molecule indicate that modification to allow binding to albumin significantly prolonged systemic exposure relative to short-acting analogues GRF(1-29), which translated into a longer duration of action and the possibility of less frequent administration in research models. In parallel, preclinical studies have shown activation of the GH/IGF-1 axis and effects on growth and body composition in GHRH-deficient animal models, further establishing the importance of CJC-1295 as a research tool in experimental endocrinology.

Also check the peptide reagent CJC-1295 NO DAC 5 mg

From a scientific characterisation perspective, the following are among the main research strengths CJC-1295 DAC 5 mg includes a well-described structural origin from GHRH, the presence of a time-extending modification and a strong grounding in performance research GH/IGF-1. At the same time, more recent regulatory analyses emphasise that the nomenclature associated with the CJC-1295 i CJC-1295 DAC sometimes inconsistent, and the safety of long-term stimulation of this pathway requires careful interpretation; potential risks associated with chronic pituitary stimulation have also been described. Therefore, interpretation of the results should take into account the experimental nature of this substance and the distinction between the form of the with DAC and variants without DAC.

You can see more information about the substance here

Scientific sources:

1. PMID 16352683 - study in healthy adults: prolonged, dose-dependent stimulation of GH and IGF-1 after CJC-1295; half-life approximately 5.8-8.1 days.
2. PMID 17018654 - work showing that pulsatile GH secretion persisted despite continuous stimulation by CJC-1295.
3. PMID 15817669 - Design and identification of CJC-1295 as a stable hGRF(1-29) extended duration analogue.
4. PMID 19386527 / PMCID PMC2787983 - preclinical studies on the activation of the GH/IGF-1 axis by CJC-1295.

The product is intended for scientific research and laboratory analysis. All articles and information on this website are for informational and educational purposes only.